Jazz Pharmaceuticals buys rights to OCD drug
Friday, 2-Feb-2007

Jazz Pharmaceuticals, Inc. and Solvay Pharmaceuticals, Inc. have announced a product license agreement under which Jazz Pharmaceuticals will have the right to market Luvox? (fluvoxamine maleate) tablets and fluvoxamine maleate extended-release capsules in the United States, upon approval by the U.S. Food and Drug Administration (FDA). Solvay Pharmaceuticals retains the right to market both products in other territories around the world.

Solvay Pharmaceuticals submitted a New Drug Application (NDA) in April 2006 to the FDA for fluvoxamine maleate extended-release capsules, an investigational compound being studied for the treatment of obsessive compulsive disorder (OCD) and generalized social anxiety disorder (SAD) in adults. Clinical data supporting the NDA are based on three clinical trials evaluating the efficacy and safety of the compound in approximately 600 patients worldwide. The application is awaiting action by the FDA.